Blood Specimen Collection Tube Shortage
The FDA updates their device shortage list to include all blood specimen collection tubes
The U.S. Food and Drug Administration (FDA) is aware the United States is experiencing significant interruptions in the supply of blood specimen collection (blood draw) tubes because of an increase in demand during the COVID-19 public health emergency and recent vendor supply challenges.
On January 19, 2022, the FDA updated the device shortage list to include all blood specimen collection tubes (product codes GIM and JKA). Previously, on June 10, 2021, the FDA added only sodium citrate (light blue top) tubes to the device shortage list.
The FDA recommends health care providers, laboratory directors, phlebotomists, and other personnel consider blood specimen collection tube conservation strategies to minimize blood collection tube use and maintain quality and safe patient care for those where testing is medically necessary.
- This press release was originally originally part of a longer FAQ article. For more information visit the U.S. Food and Drug Administration website